Gossamer Bio, Inc. reported its financial results for the first quarter of 2026, revealing a total revenue of $16.96 million, a significant increase from $9.89 million in the same period last year. This growth is primarily attributed to revenue generated from contracts with collaborators, specifically the Chiesi Collaboration Agreement, which accounted for all of the company's revenue during the quarter. Despite this increase in revenue, Gossamer Bio reported a net loss of $46.66 million, compared to a net loss of $36.64 million in the first quarter of 2025, reflecting ongoing challenges in managing operating expenses.
Operating expenses for the quarter totaled $61.82 million, up from $46.70 million in the prior year, driven by a $10.09 million increase in general and administrative expenses and a $5.03 million rise in research and development costs. The increase in general and administrative expenses was largely due to higher personnel costs, including severance payments, and increased stock-based compensation. Research and development expenses were primarily related to the ongoing clinical trials for seralutinib, the company's lead product candidate for pulmonary hypertension.
In terms of operational developments, Gossamer Bio has made strategic decisions to streamline its workforce, reducing its employee count by approximately 46% as part of a cost-cutting initiative. This workforce reduction, which began in March 2026, is expected to result in charges of about $6.1 million related to severance and other termination costs. The company aims to focus its remaining resources on the development of seralutinib and to explore potential regulatory pathways for its commercialization.
As of March 31, 2026, Gossamer Bio had cash, cash equivalents, and marketable securities totaling $99.2 million, a decrease from $172.25 million at the end of 2025. The company has indicated that its existing cash resources are not sufficient to fund operations for at least one year, raising concerns about its ability to continue as a going concern. Gossamer Bio plans to seek additional funding through equity or debt financing, collaborations, or other arrangements to support its ongoing operations and development activities.
Looking ahead, Gossamer Bio is preparing to submit a New Drug Application for seralutinib to the FDA in September 2026, contingent on the outcomes of ongoing discussions with regulatory authorities. The company remains focused on advancing its clinical programs while managing its financial resources carefully to navigate the challenges of the biopharmaceutical landscape.
About Gossamer Bio, Inc.
Gossamer Bio, Inc. is a biopharmaceutical company focused on developing therapies for pulmonary hypertension, including PAH and PH-ILD. Its lead candidate, seralutinib, is an inhaled kinase inhibitor targeting pathways involved in vascular remodeling. The company advances clinical trials, collaborates globally, and aims to provide innovative, targeted treatments for high unmet medical needs in rare pulmonary diseases.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.